Patterns of Radiotherapy Use and Outcomes in Head and Neck Soft-Tissue Sarcoma in a National Cohort.
Head and neck cancer
radiation therapy
soft-tissue sarcomas
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
21
05
2018
revised:
02
01
2019
accepted:
12
02
2019
pubmed:
21
3
2019
medline:
3
7
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
We used the National Cancer Database to identify the patterns of care and prognostic factors in adult patients with head and neck soft-tissue sarcoma (HNSTS). Retrospective cohort analysis. Using the National Cancer Database, we identified patients age ≥ 18 years who were diagnosed with HNSTS between 2004 and 2013. Both χ Our final cohort included 1,282 patients (682 treated with surgery only, 199 treated with RT only, and 401 treated with surgery and RT). Patients with younger age, poor tumor grade, rhabdomyosarcoma histology, and chemotherapy treatment were more likely to receive RT alone without surgery. Among the 1,083 surgical patients, RT utilization was associated with positive margins (odds ratio [OR]: 2.18, 95% confidence interval [CI]: 1.36-3.48), poor grade (OR: 2.92, 95% CI: 1.95-4.38), and chemotherapy use (OR: 1.78, 95% CI: 1.15-2.76). Radiotherapy utilization among surgical patients was not affected by demographic factors (age, sex, or ethnicity) or treatment institution (academic or community). For surgical patients, poor grade, large tumor size, and rhabdomyosarcoma histology were associated with worse OS on multivariate analysis. In this analysis of HNSTS, younger patients with poor tumor grade and rhabdomyosarcoma histology were more likely to receive RT without surgery. Among surgical patients, adjuvant RT was more likely to be used for positive margins and poor grade, with no demographic disparities identified. Poor grade and rhabdomyosarcoma histology were negative prognostic factors for surgical patients. NA Laryngoscope, 130:120-127, 2020.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
120-127Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Kraus DH, Dubner S, Harrison LB, et al. Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas. Cancer 1994;74:697-702.
Tejani MA, Galloway TJ, Lango M, Ridge JA, von Mehren M. Head and neck sarcomas: a comprehensive cancer center experience. Cancers (Basel) 2013;5:890-900.
Mahmoud O, Beck R, Kalyoussef E, et al. Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma: a population based study. Oral Oncol 2017;66:28-37.
Tajudeen BA, Fuller J, Lai C, et al. Head and neck sarcomas: the UCLA experience. Am J Otolaryngol 2014;35:476-481.
Fayda M, Aksu G, Yaman Agaoglu F, et al. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: review of 30 cases. J Craniomaxillofac Surg 2009;37:42-48.
Mattavelli D, Miceli R, Radaelli S, et al. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. Ann Oncol 2013;24:2181-2189.
de Bree R, van der Waal I, de Bree E, Leemans CR. Management of adult soft tissue sarcomas of the head and neck. Oral Oncol 2010;46:786-790.
Dudhat SB, Mistry RC, Varughese T, Fakih AR, Chinoy RF. Prognostic factors in head and neck soft tissue sarcomas. Cancer 2000;89:868-872.
Park JT, Roh JL, Kim SO, et al. Prognostic factors and oncological outcomes of 122 head and neck soft tissue sarcoma patients treated at a single institution. Ann Surg Oncol 2015;22:248-255.
Vitzthum LK, Brown LC, Rooney JW, Foote RL. Head and neck soft tissue sarcomas treated with radiation therapy. Rare Tumors 2016;8:61-65.
O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235-2241.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573-581.
Mahmoud O, Tunceroglu A, Chokshi R, et al. Overall survival advantage of chemotherapy and radiotherapy in the perioperative management of large extremity and trunk soft tissue sarcoma; a large database analysis. Radiother Oncol 2017;124:277-284.
Van Damme JP, Schmitz S, Machiels JP, et al. Prognostic factors and assessment of staging systems for head and neck soft tissue sarcomas in adults. Eur J Surg Oncol 2010;36:684-690.
Mendenhall WM, Mendenhall CM, Werning JW, Riggs CE, Mendenhall NP. Adult head and neck soft tissue sarcomas. Head Neck 2005;27:916-922.
Barker JL Jr, Paulino AC, Feeney S, McCulloch T, Hoffman H. Locoregional treatment for adult soft tissue sarcomas of the head and neck: an institutional review. Cancer J 2003;9:49-57.